Solubility Enhancement of Poorly Water Soluble Drug

The Biopharmaceutical Classification System includes solubility as one of its core criteria, and dissolution rate is the most crucial variable affecting a drug's bioavailability. A weakly water-soluble medication is defined as a substance with a solubility of less than 1 part per 10,000 parts of water. The medicine with poor solubility exhibits numerous issues with in-vitro formulation. Therefore, it is crucial to increase these medications' solubility by using various solubility improvement procedures. As A BCS class II medication that is essentially insoluble is glimepiride. There was very little information available for the manufacture of solid dispersion by a solvent evaporation approach for glimepiride-urea, however it was discovered that this technique is promising for improving solubility. In the current study, the similar approach was prepared employing the carriers urea and PEG 6000 to increase the solubility of glimepiride. In-vitro dissolution rates are greater for the robust formulation. In phosphate buffer pH 6.8, the in vitro dissolving ability of glimepiride and its equivalent solid dispersions was assessed. When compared to the pure medication, the solid dispersion GUS3 (glimepiride: urea; 1:3) showed the greatest increase in solubility. The tablets were put through a number of tests, and the outcomes were compared to industry standards. Comparing the GUS3 formulation to the commercial form, a greater drug release was observed. This demonstrates how the solid dispersion approach can improve the dissolution of medications that are not very water soluble.